Here’s how analysts see Cardiome Pharma Corp. (NASDAQ:CRME) after this past week.

May 18, 2018 - By Catherine Nunes

Investors sentiment decreased to 0.46 in 2017 Q4. Its down 0.63, from 1.09 in 2017Q3. It is negative, as 6 investors sold Cardiome Pharma Corp. shares while 7 reduced holdings. 2 funds opened positions while 4 raised stakes. 12.53 million shares or 7.45% less from 13.54 million shares in 2017Q3 were reported.
Westfield Capital Management Company Lp holds 0.06% in Cardiome Pharma Corp. (NASDAQ:CRME) or 4.68M shares. Deutsche Commercial Bank Ag stated it has 0% in Cardiome Pharma Corp. (NASDAQ:CRME). Virtu Llc holds 11,693 shares. Grp One Trading Limited Partnership holds 917 shares. The New York-based Knott David M has invested 0.04% in Cardiome Pharma Corp. (NASDAQ:CRME). National Bank & Trust Of America De owns 45 shares for 0% of their portfolio. Putnam Investments Limited Liability Company has invested 0.01% in Cardiome Pharma Corp. (NASDAQ:CRME). Royal Bank & Trust Of Canada holds 0% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME) for 1,233 shares. Wells Fargo Com Mn holds 800 shares. Comml Bank Of Montreal Can stated it has 0% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME). Scotia Incorporated has 19,120 shares. Clough Ltd Partnership invested 0.34% in Cardiome Pharma Corp. (NASDAQ:CRME). 51,400 were accumulated by Pnc. Alphaone Invest Serv Ltd Limited Liability Company stated it has 10,625 shares. Jpmorgan Chase And accumulated 161,450 shares or 0% of the stock.

Cardiome Pharma Corp. (NASDAQ:CRME) Ratings Coverage

Among 2 analysts covering Cardiome Pharma Corp (NASDAQ:CRME), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cardiome Pharma Corp had 5 analyst reports since November 22, 2017 according to SRatingsIntel. The stock has “Buy” rating by H.C. Wainwright on Wednesday, April 4. Mackie upgraded Cardiome Pharma Corp. (NASDAQ:CRME) on Friday, December 15 to “Buy” rating. The firm earned “Buy” rating on Wednesday, March 14 by Mackie. H.C. Wainwright maintained Cardiome Pharma Corp. (NASDAQ:CRME) rating on Thursday, May 17. H.C. Wainwright has “Buy” rating and $9.5000 target. The stock has “Buy” rating by H.C. Wainwright on Wednesday, November 22. Below is a list of Cardiome Pharma Corp. (NASDAQ:CRME) latest ratings and price target changes.

17/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $9.5000 Maintain
04/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $9.5000 Maintain
14/03/2018 Broker: Mackie Rating: Buy New Target: $2.8 Maintain
15/12/2017 Broker: Mackie Rating: Buy Upgrade
22/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.5 Maintain

The stock decreased 1.68% or $0.04 during the last trading session, reaching $2.34. About 90,444 shares traded. Cardiome Pharma Corp. (NASDAQ:CRME) has declined 27.63% since May 18, 2017 and is downtrending. It has underperformed by 39.18% the S&P500.

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. The company has market cap of $81.10 million. It offers BRINAVESS ) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. It currently has negative earnings. The firm also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension.

More notable recent Cardiome Pharma Corp. (NASDAQ:CRME) news were published by: Seekingalpha.com which released: “Cardiome up 13% premarket on United Therapeutics’ takeout of SteadyMed” on April 30, 2018, also Benzinga.com with their article: “Earnings Scheduled For May 15, 2018” published on May 15, 2018, Prnewswire.com published: “Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess® in China” on May 17, 2018. More interesting news about Cardiome Pharma Corp. (NASDAQ:CRME) were released by: Prnewswire.com and their article: “Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 …” published on May 10, 2018 as well as Seekingalpha.com‘s news article titled: “Cardiome Pharma’s (CRME) CEO William Hunter on Q1 2018 Results – Earnings Call Transcript” with publication date: May 16, 2018.

Cardiome Pharma Corp. (NASDAQ:CRME) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: